BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 22234980)

  • 1. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
    Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE
    Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas.
    Al Saati T; Clerc P; Hanoun N; Peuget S; Lulka H; Gigoux V; Capilla F; Béluchon B; Couvelard A; Selves J; Buscail L; Carrier A; Dusetti N; Dufresne M
    Am J Pathol; 2013 Jun; 182(6):1996-2004. PubMed ID: 23578383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.
    Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Dürr A; Höfler H; Klöppel G; Müller-Decker K; Brielmeier M; Esposito I
    J Pathol; 2012 Apr; 226(5):723-34. PubMed ID: 21984419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The conditional expression of KRAS G12D in mouse pancreas induces disorganization of endocrine islets prior the onset of ductal pre-cancerous lesions.
    Gout J; Pommier RM; Vincent DF; Ripoche D; Goddard-Léon S; Colombe A; Treilleux I; Valcourt U; Tomasini R; Dufresne M; Bertolino P; Bartholin L
    Pancreatology; 2013; 13(3):191-5. PubMed ID: 23719586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
    Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
    Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.
    Krantz SB; Shields MA; Dangi-Garimella S; Cheon EC; Barron MR; Hwang RF; Rao MS; Grippo PJ; Bentrem DJ; Munshi HG
    Mol Cancer Res; 2011 Oct; 9(10):1294-304. PubMed ID: 21856775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN.
    Siveke JT; Einwächter H; Sipos B; Lubeseder-Martellato C; Klöppel G; Schmid RM
    Cancer Cell; 2007 Sep; 12(3):266-79. PubMed ID: 17785207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early requirement of Rac1 in a mouse model of pancreatic cancer.
    Heid I; Lubeseder-Martellato C; Sipos B; Mazur PK; Lesina M; Schmid RM; Siveke JT
    Gastroenterology; 2011 Aug; 141(2):719-30, 730.e1-7. PubMed ID: 21684285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
    Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
    Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma.
    Uehara H; Miyamoto M; Kato K; Ebihara Y; Kaneko H; Hashimoto H; Murakami Y; Hase R; Takahashi R; Mega S; Shichinohe T; Kawarada Y; Itoh T; Okushiba S; Kondo S; Katoh H
    Cancer Res; 2004 May; 64(10):3533-7. PubMed ID: 15150108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented expression and secretion of adipose-derived pigment epithelium-derived factor does not alter local angiogenesis or contribute to the development of systemic metabolic derangements.
    Lakeland TV; Borg ML; Matzaris M; Abdelkader A; Evans RG; Watt MJ
    Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1367-77. PubMed ID: 24760990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice.
    Hase R; Miyamoto M; Uehara H; Kadoya M; Ebihara Y; Murakami Y; Takahashi R; Mega S; Li L; Shichinohe T; Kawarada Y; Kondo S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8737-44. PubMed ID: 16361561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRas(G12V)-driven pancreatic tumourigenesis.
    Flandez M; Cendrowski J; Cañamero M; Salas A; del Pozo N; Schoonjans K; Real FX
    Gut; 2014 Apr; 63(4):647-55. PubMed ID: 23598351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.